Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

1.

Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.

Han HJ, Kim BC, Lee JY, Ryu SH, Na HR, Yoon SJ, Park HY, Shin JH, Cho SJ, Yi HA, Choi MS, Heo JH, Park KW, Kim KK, Choi SH.

Dement Geriatr Cogn Disord. 2012;34(3-4):167-73. doi: 10.1159/000342927. Epub 2012 Oct 5.

PMID:
23051684
[PubMed - indexed for MEDLINE]
2.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
[PubMed - indexed for MEDLINE]
3.

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M.

Int J Geriatr Psychiatry. 2011 Dec;26(12):1236-43. doi: 10.1002/gps.2669. Epub 2010 Dec 23.

PMID:
22068922
[PubMed - indexed for MEDLINE]
4.

Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.

Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R.

Curr Med Res Opin. 2006 Mar;22(3):483-94.

PMID:
16574032
[PubMed - indexed for MEDLINE]
5.

Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.

Farlow M, Lane R, Kudaravalli S, He Y.

Pharmacogenomics J. 2004;4(5):332-5.

PMID:
15289797
[PubMed - indexed for MEDLINE]
6.

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.

Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, Lee JH; Expect Study Group.

Curr Med Res Opin. 2011 Jul;27(7):1375-83. doi: 10.1185/03007995.2011.582484. Epub 2011 May 12.

PMID:
21561398
[PubMed - indexed for MEDLINE]
7.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

PMID:
22541366
[PubMed - indexed for MEDLINE]
Free Article
8.

A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.

Articus K, Baier M, Tracik F, Kühn F, Preuss UW, Kurz A.

Int J Clin Pract. 2011 Jul;65(7):790-6. doi: 10.1111/j.1742-1241.2011.02713.x. Epub 2011 Jun 6.

PMID:
21645184
[PubMed - indexed for MEDLINE]
9.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group.

Curr Alzheimer Res. 2008 Feb;5(1):83-9.

PMID:
18288936
[PubMed - indexed for MEDLINE]
10.

Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.

Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I.

Int J Clin Pract. 2006 Jan;60(1):110-8.

PMID:
16409439
[PubMed - indexed for MEDLINE]
11.

Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.

Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I.

Dement Geriatr Cogn Disord. 2007;23(5):301-6. Epub 2007 Mar 13.

PMID:
17356273
[PubMed - indexed for MEDLINE]
12.

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.

Visser PJ, Scheltens P, Pelgrim E, Verhey FR; Dutch ENA-NL-01 Study Group.

Dement Geriatr Cogn Disord. 2005;19(2-3):126-33. Epub 2004 Dec 23.

PMID:
15627759
[PubMed - indexed for MEDLINE]
13.

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.

Grossberg GT, Olin JT, Somogyi M, Meng X.

Int J Clin Pract. 2011 Apr;65(4):465-71. doi: 10.1111/j.1742-1241.2011.02641.x. Epub 2011 Feb 11.

PMID:
21309961
[PubMed - indexed for MEDLINE]
14.

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.

Farlow MR, Alva G, Meng X, Olin JT.

Curr Med Res Opin. 2010 Feb;26(2):263-9. doi: 10.1185/03007990903434914.

PMID:
19929593
[PubMed - indexed for MEDLINE]
15.

Impact of APOE in mild cognitive impairment.

Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC.

Neurology. 2004 Nov 23;63(10):1898-901.

PMID:
15557508
[PubMed - indexed for MEDLINE]
16.

Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.

Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.

Pharmacogenet Genomics. 2006 Nov;16(11):771-4.

PMID:
17047484
[PubMed - indexed for MEDLINE]
17.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
[PubMed - indexed for MEDLINE]
18.

[Pharmacological approaches to the therapy of Alzheimer's disease].

Gavrilova SI.

Vestn Ross Akad Med Nauk. 2006;(9-10):30-4. Russian.

PMID:
17111921
[PubMed - indexed for MEDLINE]
19.

Rivastigmine for Alzheimer's disease.

Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Review.

PMID:
19370562
[PubMed - indexed for MEDLINE]
20.

BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S.

Eur J Clin Pharmacol. 2011 Nov;67(11):1147-57. doi: 10.1007/s00228-011-1064-x. Epub 2011 Jun 1.

PMID:
21630031
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk